Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
Conditions
- Lung Cancer Non-small Cell Stage IV
Sponsor
Guangzhou Institute of Respiratory Disease
Collaborators